Management of temozolomide toxicity by nurse practitioners in neuro-oncology

Oncology Nursing Forum

Volumn 36, Issue 2, 2009, Pages 225-231

  Zwinkels, Hanneke ^a   Roon, Krista ^a   Jeurissen, Frank J F ^a   Taphoorn, Martin J B ^b   Hop, Wim C J ^c   Vecht, Charles J ^b  

^a Department of Neurology ^*  (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; TEMOZOLOMIDE;

ANALYSIS OF VARIANCE; ARTICLE; BRAIN TUMOR; CHEMICALLY INDUCED DISORDER; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG MONITORING; EVALUATION; GLIOMA; HUMAN; LYMPHOCYTOPENIA; NAUSEA; NETHERLANDS; NEUTROPENIA; NONPARAMETRIC TEST; NURSE ATTITUDE; NURSE PRACTITIONER; NURSING; NURSING EVALUATION RESEARCH; ONCOLOGY NURSING; ORGANIZATION AND MANAGEMENT; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHI-SQUARE DISTRIBUTION; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; GLIOMA; HUMANS; LYMPHOPENIA; NAUSEA; NETHERLANDS; NEUTROPENIA; NURSE PRACTITIONERS; NURSE'S ROLE; NURSING EVALUATION RESEARCH; ONCOLOGIC NURSING; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 67649197517     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/09.ONF.225-231     Document Type: Article

References (20)

1. Bedell, C.H. (2003). A changing paradigm for cancer treatment: The advent of new oral chemotherapy agents. Clinical Journal of Oncology Nursing, 7(6, Suppl.), 5-9.
2. Brandes, A.A., Tosoni, A., Cavallo, G., Bertorelle, R., Gioia, V., Franceschi, E., et al. (2006). Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). British Journal of Cancer, 95(9), 1155-1160. (Pubitemid 44658477)
3. Chang, S.M., Theodosopoulos, P., Lamborn, K., Malec, M., Rabbitt, J., Page, M., et al. (2004). Temozolomide in the treatment of recurrent malignant glioma. Cancer, 100(3), 605-611. (Pubitemid 38124780)
4. Crighton, M.H. (2004). Dimensions of neutropenia in adult cancer patients: Expanding conceptualizations beyond the numerical value of the absolute neutrophil count. Cancer Nursing, 27(4), 275-284.
5. Dutch Health Care Inspectorate. (2007). State of health report 2007. Retrieved January 7, 2008, from http://www.igz.nl/34044/Staat-van-de- Gezondheidszor1.pdf
6. Dutch Health Care Inspectorate. (2007). State of health report 2007. Retrieved January 7, 2008, from http://www.igz.nl/34044/Staat-van-de- Gezondheidszor1.pdf (Pubitemid 46543488)
7. Gerber, D.E., Grossman, S.A., Zeltzman, M., Parisi, M.A., & Kleinberg, L. (2007). The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro-Oncology, 9(1), 47-52. (Pubitemid 46543488)
8. Hartigan, K. (2003). Patient education: The cornerstone of successful oral chemotherapy treatment. Clinical Journal of Oncology Nursing, 7(6, Suppl.), 21-24.
9. Hollywood, E., & Semple, D. (2001). Nursing strategies for patients on oral chemotherapy. Oncology, 15(1, Suppl. 2), 37-39. (Pubitemid 33738920)
10. Houston, D. (1997). Supportive therapies for cancer chemotherapy patients and the role of the oncology nurse. Cancer Nursing, 20(6), 409-413. (Pubitemid 27513641)
11. Jen, J.F., Cutler, D.L., Pai, S.M., Batra, V.K., Affrime, M.B., Zambas, D.N., et al. (2000). Population pharmacokinetics of temozolomide in cancer patients. Pharmaceutical Research, 17(10), 1284-1289.
12. Keime-Guibert, F., Chinot, O., Taillandier, L., Cartalat-Carel, S., Frenay, M., Kantor, G., et al. (2007). Radiotherapy for glioblastoma in the elderly. New England Journal of Medicine, 356(15), 1527-1535. (Pubitemid 46588417)
13. Kristiansen, K., Hagen, S., Kollevold, T., Torvik, A., Holme, I., Nesbakken, R.,et al. (1981). Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potention of bleomycin on survival time: A prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer, 47(4), 649-652. (Pubitemid 11135858)
14. National Cancer Institute. (2003). Common Terminology Criteria for Adverse Events: Blood and bone marrow toxicity [version 3.0]. Bethesda, MD: Author.
15. Oncology Guidelines. (2008). Retrieved February 17, 2009, from http://www.oncoline/richtlijn/item/index.php?pagina=/richtlijn/item/pagina. php&richtlijn-id=567
16. Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987-996. (Pubitemid 40349501)
17. Su, Y.B., Sohn, S., Krown, S.E., Livingston, P.O., Wolchok, J.D., Quinn, C., et al. (2004). Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications. Journal of Clinical Oncology, 22(4), 610-616. (Pubitemid 41095063)
18. Taphoorn, M.J., Stupp, R., Coens, C., Osoba, D., Kortmann, R., van den Bent, M.J., et al. (2005). Health-related quality of life in patients with glioblastoma: A randomised controlled trial. Lancet Oncology, 6(12), 937-944. (Pubitemid 41685226)
19. van den Bent, M.J., Taphoorn, M.J., Brandes, A.A., Menten, J., Stupp, R., Frenay, M., et al. (2003). Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organisation for Research and Treatment of Cancer Brain Tumor Group Study 26971. Journal of Clinical Oncology, 21(13), 2525-2528. (Pubitemid 46606334)
20. Wick, A., Felsberg, J., Steinbach, J.P., Herrlinger, U., Platten, M., Blaschke, B., et al. (2007). Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. Journal of Clinical Oncology, 25(22), 3357-3361. (Pubitemid 47325623)